New York – Sept 24 2024
Eli Lilly and Company (NYSE: LLY) has entered into a landmark $409 million research collaboration with Genetic Leap, a cutting-edge AI-driven biotech company, to accelerate the development of RNA-targeted therapeutics. This partnership leverages Genetic Leap’s proprietary artificial intelligence (AI) platform to develop oligonucleotide drugs aimed at high-priority disease targets identified by Lilly.
AI-Powered RNA Drug Discovery: A Transformational Approach
The collaboration builds on a successful pilot program between the two companies, demonstrating the potential of AI in drug development. Genetic Leap’s RNA-targeted AI platform is designed to overcome historical challenges in targeting RNA, unlocking new therapeutic opportunities.
“We are thrilled to collaborate with Lilly and share their commitment to developing RNA-based medicines,” said Dr. Bertrand Adanve, CEO and Founder of Genetic Leap. “Our mission is to accelerate the development of life-saving therapies, and this partnership brings us closer to that goal.”
Financial and Strategic Terms of the Agreement
Under the terms of the deal, Genetic Leap will receive up to $409 million in upfront, development, clinical, regulatory, and commercial milestone payments, in addition to tiered royalties on future sales of successful drugs. The agreement solidifies Eli Lilly’s commitment to expanding its portfolio of genetic medicines, which now constitute over 25% of its drug development pipeline.
Advancing RNA Medicine: A Growing Trend in Biopharma
This partnership aligns with the broader industry trend of leveraging RNA-based therapies to address diseases at their genetic roots. Eli Lilly recently expanded its investment in nucleic acid research, including the establishment of a $700 million R&D center in the Boston Seaport. The pharmaceutical giant continues to enhance its capabilities in immunology, neurodegeneration, diabetes, and obesity through AI-driven drug discovery.
The rise of RNA-based medicines has driven significant investment and M&A activity in the biotech sector. In recent years, companies such as Arrakis Therapeutics have pioneered RNA-targeting technologies, while large pharmaceutical firms, including Merck and Sanofi, have expanded their AI-driven drug development strategies.
AI and Pharma: The Future of Drug Discovery
Eli Lilly’s partnership with Genetic Leap reflects a broader shift toward AI-driven collaborations in the pharmaceutical industry. This year, Lilly also announced a partnership with OpenAI to explore generative AI in antimicrobial drug discovery, further cementing its commitment to technological innovation in biopharma.
About Genetic Leap
Genetic Leap is an AI-native biotech company focused on revolutionizing drug discovery through advanced machine learning models targeting RNA-based therapies. By combining AI with deep biological insights, Genetic Leap is developing novel therapeutics for previously undruggable targets.
More about news
By
